)
Company Research3 May 2024
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
BioNTech
BioNTech (BNTX) investor relations material
BioNTech 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Strategic achievements and financial position
Delivered five billion vaccine doses globally, launched a variant-adapted COVID-19 vaccine, and maintained over 50% global market share in key regions.
Executed key partnerships, notably with Bristol Myers Squibb, and acquired Biotheus and CureVac.
Ended 2025 with a cash balance of €17.2 billion and over $17 billion in cash and equivalents.
Increased 2025 revenue guidance to €2.6–2.8 billion, with high-margin COVID-19 vaccine business funding oncology innovation.
Revenues from COVID vaccines are being used to finance oncology programs, with disciplined resource allocation.
Oncology pipeline and development strategy
Over 25 ongoing phase 2 and 3 oncology trials, with 15–17 late-stage/pivotal readouts expected in 2026–2027.
Key assets include Prometimic/Pumitamig (PD-L1 x VEGF bispecific), Gotistobart (CTLA-4 Treg depleter), and BNT324/DB-1311 (B7-H3 ADC).
Pursuing synergy-driven approaches across immunomodulators, ADCs, and mRNA cancer immunotherapies.
Tumor-centric development is prioritized, focusing on high-prevalence solid tumors and unmet medical needs.
Building a multi-product oncology company by 2030, targeting broad late-stage acceleration and combination therapy momentum.
Clinical data and upcoming milestones
Prometimic/Pumitamig shows efficacy across 18 tumor types, with over 1,600 patients studied and 8 pivotal studies ongoing.
Gotistobart demonstrated a 54% reduction in risk of death in CPI-treated squamous NSCLC; pivotal phase 3 data expected in 2026.
BNT324/DB-1311 demonstrates strong antitumor activity and favorable safety in mCRPC, with phase 3 trial planned for 2026.
Over 15 data readouts anticipated in 2026, including pivotal and early-stage combination trials.
mRNA immunotherapies (Autogene Cevumeran, FixVac) induce broad T cell responses and show survival benefit in early trials.
Gotistobart's path to chemo-free 2L NSCLC?
How will tumor-centric approach impact pipeline?
Which 2026 readouts are most impactful?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BioNTech earnings date
Q4 202510 Mar, 2026
BioNTech
Next BioNTech earnings date
Q4 202510 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. Additionaly its clinical development will target the treatment of infectious diseases, including prophylactic vaccine approach that includes mRNA. It is also developing various neoantigen-based immunotherapies in collaboration with Pfizer Inc.; other checkpoint molecules; and next-generation antigen receptor T-cell products. The company was formerly known as BioNtech Therapeutics GmbH. BioNTech SE was founded in 2008 and is headquartered in Mainz, Germany.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage